NASDAQ: RARE
Ultragenyx Pharmaceutical Inc Earnings Dates, Reports, Calls

Ultragenyx Pharmaceutical earnings were -$559.0M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest RARE earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$133.5M, up 1.5% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, RARE reported annual earnings of -$606.6M, with -14.2% growth. The next RARE earnings date is Feb 13, 2025.

RARE earnings history

Current Revenue
$522.7M
Current Earnings
-$559.0M
Current Profit Margin
-106.9%

RARE Return on Equity

Current Company
-188.2%
Current Industry
19.9%
Current Market
35%
RARE's Return on Equity (-188.2%)... subscribe to Premium to read more.
High Return on Equity Performance

RARE Return on Assets

Current Company
-37.5%
Current Industry
1.3%
RARE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when RARE announces earnings.

RARE Return on Capital Employed

Current Company
-44.77%
Current Industry
14.3%
RARE's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RARE vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
RARE-$526.39M-$558.99MN/A-$6.39
VKTX-$98.84M-$99.15MN/A-$0.93
BHVN-$797.57M-$804.34MN/A-$9.41
ADMA$98.83M$68.13MN/A$0.29
SRRK-$218.14M-$225.97MN/A-$2.35

RARE earnings dates

Next earnings date
Feb 13, 2025

Ultragenyx Pharmaceutical Earnings Reports & History FAQ

What were Ultragenyx Pharmaceutical's earnings last quarter?

On RARE's earnings call on Invalid Date, Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q3 2024 earnings per share (EPS) of -$1.40, up 37.22% year over year. Total RARE earnings for the quarter were -$133.52 million. In the same quarter last year, Ultragenyx Pharmaceutical's earnings per share (EPS) was -$2.23.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.

When does Ultragenyx Pharmaceutical report earnings?

The next RARE earnings date is Invalid Date. Add RARE to your watchlist to be reminded of Ultragenyx Pharmaceutical's next earnings date.

What was RARE's earnings growth in the past year?

As of Ultragenyx Pharmaceutical's earnings date in Invalid Date, Ultragenyx Pharmaceutical's earnings has grown year over year. RARE earnings in the past year totalled -$558.99 million.

Is Ultragenyx Pharmaceutical profitable or losing money?

As of the last Ultragenyx Pharmaceutical earnings report, Ultragenyx Pharmaceutical is currently losing money. Ultragenyx Pharmaceutical's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$558.99 million, a 12.01% decrease year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.